Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189773485> ?p ?o ?g. }
- W3189773485 abstract "It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress human immunodeficiency virus (HIV) replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n = 100, n = 124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either an NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4+ count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically measured adherence to ART.In both cohorts, levels of CA HIV RNA and DNA strongly correlated (rho = 0.70 and rho = 0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (padj = 0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (padj = 0.048 and padj = 0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals.All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.This work was supported by ZonMw (09120011910035) and FP7 Health (305522)." @default.
- W3189773485 created "2021-08-16" @default.
- W3189773485 creator A5000465145 @default.
- W3189773485 creator A5001062393 @default.
- W3189773485 creator A5001375239 @default.
- W3189773485 creator A5002814671 @default.
- W3189773485 creator A5006672025 @default.
- W3189773485 creator A5007616376 @default.
- W3189773485 creator A5008912450 @default.
- W3189773485 creator A5009615069 @default.
- W3189773485 creator A5012546911 @default.
- W3189773485 creator A5013085782 @default.
- W3189773485 creator A5013690116 @default.
- W3189773485 creator A5013768096 @default.
- W3189773485 creator A5013780093 @default.
- W3189773485 creator A5014008798 @default.
- W3189773485 creator A5014652532 @default.
- W3189773485 creator A5015546063 @default.
- W3189773485 creator A5018543793 @default.
- W3189773485 creator A5018565033 @default.
- W3189773485 creator A5018714528 @default.
- W3189773485 creator A5019287445 @default.
- W3189773485 creator A5020621291 @default.
- W3189773485 creator A5021169959 @default.
- W3189773485 creator A5021198510 @default.
- W3189773485 creator A5021568119 @default.
- W3189773485 creator A5021983212 @default.
- W3189773485 creator A5022674941 @default.
- W3189773485 creator A5025109424 @default.
- W3189773485 creator A5025357636 @default.
- W3189773485 creator A5025931713 @default.
- W3189773485 creator A5026409919 @default.
- W3189773485 creator A5027821265 @default.
- W3189773485 creator A5028419646 @default.
- W3189773485 creator A5029062441 @default.
- W3189773485 creator A5030171827 @default.
- W3189773485 creator A5030201334 @default.
- W3189773485 creator A5032678906 @default.
- W3189773485 creator A5034281578 @default.
- W3189773485 creator A5034500942 @default.
- W3189773485 creator A5036826137 @default.
- W3189773485 creator A5037515331 @default.
- W3189773485 creator A5039302045 @default.
- W3189773485 creator A5039721541 @default.
- W3189773485 creator A5039738554 @default.
- W3189773485 creator A5040038561 @default.
- W3189773485 creator A5040644400 @default.
- W3189773485 creator A5041859079 @default.
- W3189773485 creator A5045157191 @default.
- W3189773485 creator A5045462199 @default.
- W3189773485 creator A5046068486 @default.
- W3189773485 creator A5046935005 @default.
- W3189773485 creator A5047002646 @default.
- W3189773485 creator A5048330851 @default.
- W3189773485 creator A5052209499 @default.
- W3189773485 creator A5053328796 @default.
- W3189773485 creator A5053375235 @default.
- W3189773485 creator A5053879179 @default.
- W3189773485 creator A5054645317 @default.
- W3189773485 creator A5060604019 @default.
- W3189773485 creator A5061628400 @default.
- W3189773485 creator A5061658006 @default.
- W3189773485 creator A5062816886 @default.
- W3189773485 creator A5064503302 @default.
- W3189773485 creator A5064926938 @default.
- W3189773485 creator A5064987589 @default.
- W3189773485 creator A5066523822 @default.
- W3189773485 creator A5070936460 @default.
- W3189773485 creator A5071696390 @default.
- W3189773485 creator A5071734115 @default.
- W3189773485 creator A5072096091 @default.
- W3189773485 creator A5075249420 @default.
- W3189773485 creator A5078302741 @default.
- W3189773485 creator A5079766290 @default.
- W3189773485 creator A5080091467 @default.
- W3189773485 creator A5081536507 @default.
- W3189773485 creator A5082400400 @default.
- W3189773485 creator A5082840819 @default.
- W3189773485 creator A5084148999 @default.
- W3189773485 creator A5086749586 @default.
- W3189773485 creator A5088840439 @default.
- W3189773485 creator A5089460804 @default.
- W3189773485 creator A5090088463 @default.
- W3189773485 creator A5090242001 @default.
- W3189773485 creator A5091197806 @default.
- W3189773485 creator A5091292847 @default.
- W3189773485 creator A5016247323 @default.
- W3189773485 date "2021-08-13" @default.
- W3189773485 modified "2023-10-17" @default.
- W3189773485 title "Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy" @default.
- W3189773485 cites W162579416 @default.
- W3189773485 cites W1967548282 @default.
- W3189773485 cites W2005141763 @default.
- W3189773485 cites W2007607803 @default.
- W3189773485 cites W2051269276 @default.
- W3189773485 cites W2054908871 @default.
- W3189773485 cites W2064140898 @default.
- W3189773485 cites W2064416623 @default.
- W3189773485 cites W2070036973 @default.
- W3189773485 cites W2089692155 @default.